Antihistamine for use in treatment of breast cancer

• US 10,456,388 B2
• Filed: 01/19/2016
• Issued: 10/29/2019
• Est. Priority Date: 01/19/2015
• Status: Active Grant

• Current Assignee: Belina Pharma AB
• Original Assignee: Belina Pharma AB
• Inventors: Olsson, Hakan, Einefors, Rickard
• Primary Examiner(s): Barsky, Jared
• Application Number:
  US15/544,575
• Publication Number:
  US 20180008588A1
• Time in Patent Office: 1,379 Days
• Field of Search: None
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/4515 having a butyrophenone group in position 1, e.g. haloperidol pipamperone A61K31/4545
• CPC Class Codes: A61K 31/4545 containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Disclosed herein is desloratadine or ebastin for use in treatment of a patient diagnosed with breast cancer. Also disclosed is desloratadine or ebastin for use in treatment of a patient diagnosed with a cancer type susceptible to immunotherapy.

Claims

1. A method of treating breast cancer in a patient diagnosed with breast cancer, the method consisting of administering to the patient an effective amount of desloratadine, wherein the breast cancer is selected from the group consisting of positive and negative ER, PR, her2 breast cancer molecular subtypes, and invasive breast carcinomas, and wherein the patient is not diagnosed with a seasonal allergic condition.

2. The method of claim 1, wherein the breast cancer is selected from the group consisting of positive and negative ER invasive breast carcinomas.

3. The method of claim 1, wherein the treatment is continuous for at least 50 days.

4. The method of claim 1, wherein said treatment improves the prognosis for the patient diagnosed with breast cancer.

5. The method of claim 1, wherein said treatment increases the survival time for the patient diagnosed with breast cancer.

6. The method of claim 1, wherein the daily dose of the desloratadine corresponds to the defined daily dose (DDD).

7. The method of claim 1, wherein the dose of the desloratadine is between 2.5 to 45 mg per day.

8. The method of claim 1, wherein the dose of the desloratadine is between 45 to 250 mg per day.

9. The method of claim 1, wherein the patient is perioperational.